Vimarsana
Biggest News Aggregation in the World

Caroline Germa News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Caroline Germa. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Caroline Germa Today - Breaking & Trending Today

Agilent at AACR 2024: Empowering Breakthroughs in Cancer Research and Diagnostics -April 03, 2024 at 08:03 am EDT - Vimarsana News

Agilent at AACR 2024: Empowering Breakthroughs in Cancer Research and Diagnostics -April 03, 2024 at 08:03 am EDT

Agilent Technologies Inc. , a global leader in life sciences and diagnostics, announced today its participation in the American Association for Cancer Research Annual Meeting . At the meeting, which...

Ikena Oncology Reports Fourth Quarter and Full Year 2023 Financial Results - Vimarsana News

Ikena Oncology Reports Fourth Quarter and Full Year 2023 Financial Results

12.03.2024 - IK-930 continues to advance in the clinic now with an optimized formulation with improved pharmacokinetics IK-930 clinical update planned for 2H 2024 including additional data from EHE patients in dose escalation and initial mesothelioma patient ...

Ikena Oncology Appoints Caroline Germa, M.D. as Chief Medical Officer - Vimarsana News

Ikena Oncology Appoints Caroline Germa, M.D. as Chief Medical Officer

Caroline Germa, M.D., an accomplished senior executive and medical oncologist, brings over 25 years of pharmaceutical and drug development expertise

Transcenta Unveils Updated Efficacy Data from Osemitamab (TST001) Plus CAPOX as First-Line Treatment for G/GEJ Cancer Study at ESMO 2023 - Vimarsana News

Transcenta Unveils Updated Efficacy Data from Osemitamab (TST001) Plus CAPOX as First-Line Treatment for G/GEJ Cancer Study at ESMO 2023

Latest data reveals a 55% confirmed response rate, median duration of response (DoR) and median progression-free survival (PFS) of more than 12 months for all

FDA Grants Transcenta Clearance to Proceed with Global Phase III Trial of Osemitamab (TST001) as First-Line Treatment for Gastric/Gastroesophageal Cancer Patients - Vimarsana News

FDA Grants Transcenta Clearance to Proceed with Global Phase III Trial of Osemitamab (TST001) as First-Line Treatment for Gastric/Gastroesophageal Cancer Patients

/PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in...